Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases
Description
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. MeSH
Hierarchy View
Subtype Terms (29)
Addison Disease
10 drugs (8 approved, 2 experimental)
Anemia, Hemolytic, Autoimmune
44 drugs (27 approved, 17 experimental)
Anti-Glomerular Basement Membrane Disease
2 drugs (1 approved, 1 experimental)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
33 drugs (27 approved, 6 experimental)
Antiphospholipid Syndrome
29 drugs (22 approved, 7 experimental)
Arthritis, Juvenile
85 drugs (64 approved, 21 experimental)
Arthritis, Rheumatoid
581 drugs (233 approved, 348 experimental)
Autoimmune Diseases of the Nervous System
18 drugs (12 approved, 6 experimental)
Autoimmune Lymphoproliferative Syndrome
5 approved drugs
Autoimmune Pancreatitis
2 approved drugs
Birdshot Chorioretinopathy
2 approved drugs
Dermatitis Herpetiformis
9 drugs (7 approved, 2 experimental)
Diabetes Mellitus, Type 1
404 drugs (205 approved, 199 experimental)
Glomerulonephritis, IGA
70 drugs (40 approved, 30 experimental)
Glomerulonephritis, Membranous
34 drugs (23 approved, 11 experimental)
Graves Disease
32 drugs (22 approved, 10 experimental)
Hepatitis, Autoimmune
26 drugs (15 approved, 11 experimental)
Immunoglobulin G4-Related Disease
20 drugs (15 approved, 5 experimental)
Latent Autoimmune Diabetes in Adults
5 drugs (4 approved, 1 experimental)
Linear IgA Bullous Dermatosis
3 drugs (1 approved, 2 experimental)
Lupus Erythematosus, Systemic
272 drugs (122 approved, 150 experimental)
Ophthalmia, Sympathetic
3 approved drugs
Pemphigoid, Bullous
30 drugs (22 approved, 8 experimental)
Pemphigus
37 drugs (23 approved, 14 experimental)
Polyendocrinopathies, Autoimmune
1 approved drug
Purpura, Thrombocytopenic, Idiopathic
94 drugs (62 approved, 32 experimental)
Thyroiditis, Autoimmune
9 drugs (6 approved, 3 experimental)
Undifferentiated Connective Tissue Diseases
4 approved drugs
Phase 3 Indicated Drugs (17)
Phase 1 Indicated Drugs (37)
Other Experimental Indicated Drugs (21)
Organization Involved with Phase 4 Indications (15)
Organization Involved with Phase 3 Indications (26)
Organization Involved with Phase 2 Indications (44)
Groupe Francophone des Myelodysplasies
Juvenile Diabetes Research Foundation
Organization Involved with Phase 1 Indications (29)
Organization Involved with Other Experimental Indications (14)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
